Savara Inc. Faces Class Action Lawsuit Ahead of Deadline
Bragar Eagel & Squire, P.C., a law firm renowned for advocating for stockholders, is bringing attention to a noteworthy class action lawsuit involving Savara Inc. (NASDAQ: SVRA). This lawsuit is significant for individuals who invested in Savara's stock during a specific period and are now grappling with potential losses due to undisclosed issues regarding the company’s filings.
Understanding the Class Action Lawsuit
The class action has been initiated in the United States District Court for the Eastern District of Pennsylvania, representing now includes all individuals and entities who acquired Savara securities between March 7, 2024, and May 23, 2025. A crucial detail for interested participants is that they have until November 7, 2025, to submit their applications to be recognized as lead plaintiffs in the ongoing lawsuit.
Key Allegations Against Savara Inc.
The lawsuit alleges that throughout the class period, Savara did not provide critical information about its Biologics License Application (BLA) for the MOLBREEVI product. This includes significant omissions regarding the application’s completeness and the anticipated approval timelines. The allegations point out that Savara was unlikely to fulfill its commitments to complete the BLA submission as promised, leading to damaging consequences for investors who relied on this information.
Impact of the Allegations
On May 27, 2025, Savara faced a significant market reaction when it reported receiving a refusal-to-file (RTF) letter from the FDA. This announcement revealed that the FDA determined the submission lacked essential data, creating immediate concern among investors. Consequently, Savara's share price experienced a drastic decline, emphasizing the substantial impact of the allegations. Following the news, shares dropped $0.90, approximately 31.69%, closing prices at $1.94.
What Should Investors Do?
For those who purchased or otherwise acquired shares of Savara and feel impacted, it’s crucial to stay informed about the proceedings. Long-term stockholders, as well as those with pertinent information regarding these claims, are encouraged to contact the attorneys at Bragar Eagel & Squire. The firm offers a no-obligation consultation regarding these matters, which could be invaluable given the nature of the lawsuit.
Contact Information for Savara Investors
Investors are advised to reach out to Brandon Walker or Marion Passmore directly via phone at (212) 355-4648 or through email at investigations@bespc.com. The law firm is experienced in these matters and can provide necessary guidance for navigating the legal landscape.
Overview of Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire, P.C. is a law firm significant in the landscape of investment protection. With well-established offices in several states, they represent both individual and institutional investors in various litigation scenarios, including securities disputes. Their expertise extends across numerous complexities in state and federal courts, and they remain a steadfast advocate for stockholders’ rights.
Frequently Asked Questions
What is the deadline for the class action lawsuit against Savara?
The deadline to apply to be a lead plaintiff in the lawsuit against Savara is November 7, 2025.
What allegations are made against Savara in the lawsuit?
The lawsuit alleges that Savara failed to adequately disclose critical information about the completeness of its Biologics License Application.
How did the market react to Savara's recent disclosures?
Following the company’s announcement of a refusal-to-file letter from the FDA, Savara's stock fell significantly, highlighting investor concern.
Who can participate in the class action lawsuit?
All individuals and entities who purchased or acquired Savara securities during the class period from March 7, 2024, to May 23, 2025, are eligible to participate.
How can investors get more information regarding their rights?
Investors can contact the law firm Bragar Eagel & Squire for consultations and information on their rights related to this lawsuit.
